Effect of a Plant-based Ingredient on Generalized Hormonal Responses
Studieöversikt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Studietyp
Studietyp
Inskrivning (Faktisk)
Inskrivning
Fas
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Gieres, Frankrike
- Eurofins Optimed Clinical research
-
-
Deltagandekriterier
Urvalskriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Healthy males, Age at start of the study >20 and <50 years;
- Body mass index (BMI) ≥ 20,0 and ≤ 25,0 kg/m2;
- Apparently healthy: no medical conditions which might affect the study measurements, absorption, metabolism and distribution (including diabetes type 1 and type 2, gastrointestinal dysfunction, gastrointestinal surgery and inflammatory diseases);
- Fasting blood glucose value of subjects is ≥ 3.4 and ≤ 6.1 mmol/litre (i.e. 62-110 mg/dl) at screening;
- Agreeing to be informed about medically relevant personal test-results by a physician;
- Informed consent signed;
- Willing to comply to study protocol during study;
- Covered by Health Insurance System and/or in compliance with the recommendations of National Law in force relating to biomedical research.
- Accessible veins on arms as determined by examination at screening.
Exclusion Criteria:
- Any history of diabetes, hyper- (or hypo-) glycemia or other disorder of glucose metabolism;
- Blood donation in the past 2 months;
- Reported participation in another nutritional or biomedical trial 3 months before the pre-study examination or during the study;
- Reported participation in night shift work two weeks prior to pre-study investigation or during the study. Night work is defined as working between midnight and 6.00 AM;
- Reported intense sporting activities > 10h/w;
- Consumption of > 21 alcoholic drinks in a typical week;
- Not being used to eat breakfast;
- Reported use of any nicotine containing products in the six months preceding the study and during the study itself;
- Use of medication which interferes with study measurements;
- Reported dietary habits: medically prescribed diet, slimming diet;
- Not used to eat 3 meals a day;
- Vegetarian;
- Reported weight loss/gain (>10%) in the last six month before the study;
- Being an employee of Unilever and CRO;
- Allergy or intolerance to food products and aversion to food products provided during the study;
- Subject who cannot be contacted in case of emergency;
- Subject who, in the judgment of the investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development;
- Subject under guardianship;
- Subject who would receive more than 4500 euro's as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Enda
Antal vapen
Vapen och interventioner
Deltagargrupp / ArmDeltagargrupp / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Övrig: Plant-based ingredient to a starchy meal
Plant-based ingredient
|
|
|
Övrig: Starchy meal alone
No plant-based ingredient
|
Vad mäter studien?
Primära resultatmått
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
AUC of post-prandial hormones
Tidsram: 120 minutes
|
Amylin (total) will be assessed.
|
120 minutes
|
|
AUC of post-prandial hormones
Tidsram: 120 minutes
|
Ghrelin (active) will be assessed.
|
120 minutes
|
|
AUC of post-prandial hormones
Tidsram: 120 minutes
|
Glucose-dependent insulinotropic peptide (gastric inhibitory polypeptide, GIP) (total) will be assessed.
|
120 minutes
|
|
AUC of post-prandial hormones
Tidsram: 120 minutes
|
Glucagon-like peptide-1 (GLP-1) (active) will be assessed.
|
120 minutes
|
|
AUC of post-prandial hormones
Tidsram: 120 minutes
|
Leptin will be assessed.
|
120 minutes
|
|
AUC of post-prandial hormones
Tidsram: 120 minutes
|
Pancreatic polypeptide (PP) will be assessed.
|
120 minutes
|
|
AUC of post-prandial hormones
Tidsram: 120 minutes
|
Peptide YY (PYY) (total) will be assessed.
|
120 minutes
|
|
AUC of post-prandial hormones
Tidsram: 120 minutes
|
Insulin will be assessed.
|
120 minutes
|
|
AUC of post-prandial hormones
Tidsram: 120 minutes
|
C-peptide will be assessed.
|
120 minutes
|
|
AUC of post-prandial hormones
Tidsram: 120 minutes
|
Glucagon will be assessed.
|
120 minutes
|
Sekundära resultatmått
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
AUC of post-prandial hormones
Tidsram: 180 and 240 minutes
|
Amylin (total) will be assessed.
|
180 and 240 minutes
|
|
AUC of post-prandial hormones
Tidsram: 180 and 240 minutes
|
Ghrelin (active) will be assessed.
|
180 and 240 minutes
|
|
AUC of post-prandial hormones
Tidsram: 180 and 240 minutes
|
Glucose-dependent insulinotropic peptide (gastric inhibitory polypeptide, GIP) (total) will be assessed.
|
180 and 240 minutes
|
|
AUC of post-prandial hormones
Tidsram: 180 and 240 minutes
|
Pancreatic polypeptide (PP) will be assessed.
|
180 and 240 minutes
|
|
AUC of post-prandial hormones
Tidsram: 180 and 240 minutes
|
Peptide YY (PYY) (total) will be assessed.
|
180 and 240 minutes
|
|
AUC of post-prandial hormones
Tidsram: 180 and 240 minutes
|
Leptin will be assessed.
|
180 and 240 minutes
|
|
AUC of post-prandial hormones
Tidsram: 180 and 240 minutes
|
Glucagon will be assessed.
|
180 and 240 minutes
|
|
AUC of post-prandial hormones
Tidsram: 180 and 240 minutes
|
Insulin will be assessed.
|
180 and 240 minutes
|
|
AUC of post-prandial hormones
Tidsram: 180 and 240 minutes
|
C-peptide will be assessed.
|
180 and 240 minutes
|
|
AUC of post-prandial hormones
Tidsram: 180 and 240 minutes
|
Glucagon-like peptide-1 (GLP-1) (active) will be assessed.
|
180 and 240 minutes
|
Andra resultatmått
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Blood glucose response (+iAUC)
Tidsram: 120 and 180 minutes
|
Effect on blood glucose response.
|
120 and 180 minutes
|
Samarbetspartners och utredare
Sponsor
Sponsor
Utredare
Utredare
- Huvudutredare: Yves DONAZZOLO, M.D., M.Sc., EUROFINS OPTIMED, GIERES - France
Studieavstämningsdatum
Studera stora datum
Studiestart
Studiestart
Primärt slutförande (Faktisk)
Primärt slutförande
Avslutad studie (Faktisk)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Första postat
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste uppdatering publicerad
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
Andra studie-ID-nummer
- FDS-NAA-1462
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .